NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
Clinical Trials
25 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06349044 2024-08-27
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Zhejiang Cancer Hospital
Phase NA Recruiting
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT00658593 2023-08-04
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
Canadian Cancer Trials Group
Phase 3 Terminated
NCT05976568 2023-08-04
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT03578874 2020-04-09
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
The University of Hong Kong
Phase 2 Completed
NCT00003867 2018-09-10
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT02042443 2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2 Completed
NCT02089633 2017-07-28
PACOX
Bio-Cancer Treatment International Limited
Phase 2 Completed
NCT00483405 2017-07-12
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03114085 2017-05-15
Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Unknown
NCT02576964 2016-11-02
A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT02403544 2016-01-05
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
ChineseAMS
Phase 1 Unknown
NCT00021047 2012-03-08
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01245582 2011-11-09
SECOX
Sanofi
Phase 3 Withdrawn
NCT00010023 2011-04-05
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Phase 1 Completed
NCT00561522 2010-07-21
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
Fudan University
Phase 2/3 Unknown
NCT00752063 2008-09-15
SECOX
The University of Hong Kong
Phase 2 Unknown
NCT00351195 2008-08-26
Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
Rigshospitalet, Denmark
Phase 2 Terminated
NCT00635323 2008-04-07
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT00464295 2007-12-14
HCC-CAP
Aga Khan University
Phase 2 Completed
NCT00076609 2007-03-28
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
PhytoCeutica
Phase 1/2 Completed